AbbVie Inc. · 2023 Q2
ReportedJul 27, 2023
Period endedJun 30, 2023
Rule of 40+39
Reported this quarter
Revenue
$13.87B
QoQ +13.4%
YoY -4.9%
EPS
$1.14
QoQ +776.9%
YoY +123.5%
Free Cash Flow
$6.14B
QoQ +52.8%
YoY +26.3%
Gross Margin
69.4%
QoQ +2.0 pp
YoY -2.0 pp
FCF Margin
44.3%
QoQ +11.4 pp
YoY +11.0 pp
P/E Ratio
25.1
QoQ -25.7%
YoY +32.7%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1551152.
HTML
8-K results announcement
Filed Jul 27, 2023
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
448 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Jun 30, 2023, filed Aug 7, 2023
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure ABBV has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for 2023 Q2, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings